文献速递前列腺癌

侵袭性去势抵抗性前列腺癌变异型新型模型的建立

Development of Novel Models of Aggressive Variants of Castration-resistant Prostate Cancer.
PubMed 文献 · Eur Urol Oncol · 2023-10-27

研究从51例转移性前列腺癌患者建立神经内分泌前列腺癌(NEPC,n=5)、DNA损伤修复(DDR,n=7)和微卫星不稳定(MSI)高(n=1)的患者来源异种移植(PDX)模型,并开发PDX来源类器官(PDXO,n=16)和患者来源类器官(PDO,n=6)用于药物筛选。模型保留了常见和罕见分子表型、驱动基因改变及瘤内异质性,并保持匹配组织的药物敏感性,可用于预测肿瘤对抗癌治疗的反应和研究耐药机制。

要点

  • 成功建立NEPC、DDR和MSI-high等侵袭性变异型前列腺癌PDX模型。
  • PDXO和PDO保留匹配组织的药物敏感性,可用于药物筛选。
  • 模型再现肿瘤分子异质性,WES显示保留多数遗传驱动改变。

核心结论

  • 模型再现常见和侵袭性前列腺癌变异型的表型与基因组特征,并捕获其分子异质性。
  • 成功建立的侵袭性变异型前列腺癌临床前模型为预测肿瘤对抗癌治疗的反应和研究耐药机制提供重要工具。

研究设计与样本

  • 从51例转移性前列腺癌患者建立PDX模型,包括NEPC(n=5)、DDR(n=7)和MSI-high(n=1)。
  • 开发PDXO(n=16)和PDO(n=6)用于药物筛选,并进行组织病理学和治疗反应表征。
  • 分子谱分析采用全外显子组测序(WES;n=13)、RNA测序(RNA-seq;n=13)和单细胞RNA-seq(n=14)。
  • 将患者肿瘤的WES和RNA-seq数据与模型进行比较。

主要发现

  • PDX捕获常见和罕见分子表型及其分子驱动因素,包括BRCA2、CDK12改变、MSI-high状态和NEPC。
  • RNA-seq分析显示广泛代表前列腺癌亚型。
  • 单细胞RNA-seq表明PDX再现细胞和分子水平的瘤内异质性。
  • 匹配患者肿瘤的WES显示多数遗传驱动改变得以保留。
  • PDXO和PDO保留匹配组织的药物敏感性,并可用于确定药物敏感性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Genomic studies have identified new subsets of aggressive prostate cancer (PCa) with poor prognosis (eg, neuroendocrine prostate cancer [NEPC], PCa with DNA damage response [DDR] alterations, or PCa resistant to androgen receptor pathway inhibitors [ARPIs]). Development of novel therapies relies on the availability of relevant preclinical models. OBJECTIVE: To develop new preclinical models (patient-derived xenograft [PDX], PDX-derived organoid [PDXO], and patient-derived organoid [PDO]) representative of the most aggressive variants of PCa and to develop a new drug evaluation strategy. DESIGN, SETTING, AND PARTICIPANTS: NEPC (n = 5), DDR (n = 7), and microsatellite instability (MSI)-high (n = 1) PDXs were established from 51 patients with metastatic PCa; PDXOs (n = 16) and PDOs (n = 6) were developed to perform drug screening. Histopathology and treatment response were characterized. Molecular profiling was performed by whole-exome sequencing (WES; n = 13), RNA sequencing (RNA-seq; n = 13), and single-cell RNA-seq (n = 14). WES and RNA-seq data from patient tumors were compared with the models. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Relationships with outcome were analyzed using the multivariable chi-square test and the tumor growth inhibition test. RESULTS AND LIMITATIONS: Our PDXs captured both common and rare molecular phenotypes and their molecular drivers, including alterations of BRCA2, CDK12, MSI-high status, and NEPC. RNA-seq profiling demonstrated broad representation of PCa subtypes. Single-cell RNA-seq indicates that PDXs reproduce cellular and molecular intratumor heterogeneity. WES of matched patient tumors showed preservation of most genetic driver alterations. PDXOs and PDOs preserve drug sensitivity of the matched tissue and can be used to determine drug sensitivity. CONCLUSIONS: Our models reproduce the phenotypic and genomic features of both common and aggressive PCa variants and capture their molecular heterogeneity. Successfully developed aggressive-variant PCa preclinical models provide an important tool for predicting tumor response to anticancer therapy and studying resistance mechanisms. PATIENT SUMMARY: In this report, we looked at the outcomes of preclinical models from patients with metastatic prostate cancer enrolled in the MATCH-R trial (NCT02517892).

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Bigot L, Sabio J, Poiraudeau L, et al. Development of Novel Models of Aggressive Variants of Castration-resistant Prostate Cancer. Eur Urol Oncol. 2023. PMID: 38433714. doi:10.1016/j.euo.2023.10.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。